Age 30–64 years | Age 65–74 years | |||||||||||||||
Income tertile | Educational level | Income tertile | Educational level | |||||||||||||
High | Medium | Low | p | High | Medium | Low | p | High | Medium | Low | p | High | Medium | Low | p | |
Number | 5738 | 5723 | 5721 | 2323 | 7199 | 7660 | ∗ | 4000 | 3990 | 3988 | 1107 | 3453 | 7418 | ∗ | ||
% | 33.4 | 33.3 | 33.3 | 13.5 | 41.9 | 44.6 | 33.4 | 33.3 | 33.3 | 9.2 | 28.8 | 61.9 | ||||
Male (%) | 84.2 | 77.7 | 67.4 | ∗ | 82.7 | 84.3 | 67.1 | ∗ | 74.0 | 64.4 | 55.1 | ∗ | 79.0 | 77.4 | 56.4 | ∗ |
Mean age (years) | 53.0 | 53.7 | 56.1 | ∗ | 53.9 | 53.6 | 55.1 | ∗ | 68.9 | 69.6 | 70.5 | ∗ | 69.5 | 69.3 | 69.8 | ∗ |
Mean observation period (years) | 4.1 | 4.3 | 4.0 | ∗ | 4.1 | 4.1 | 4.1 | 3.7 | 3.5 | 3.7 | 3.6 | 3.5 | 3.7 | |||
Living alone (%) | 19.5 | 17.3 | 35.1 | ∗ | 21.9 | 20.4 | 28.0 | ∗ | 28.0 | 34.3 | 30.7 | ∗ | 24.9 | 25.5 | 34.5 | ∗ |
Drug use before admission† | ||||||||||||||||
Statins (%) | 4.5 | 4.2 | 5.1 | 4.5 | 4.5 | 4.7 | 4.6 | 4.8 | 3.9 | 5.1 | 5.0 | 4.1 | ∗ | |||
Beta-blockers (%) | 9.9 | 9.9 | 11.5 | ∗ | 9.8 | 10.7 | 10.4 | 14.0 | 13.7 | 14.8 | 13.5 | 14.0 | 14.4 | |||
Co-morbidity‡ | ||||||||||||||||
COPD + asthma (%) | 1.1 | 1.8 | 4.8 | ∗ | 1.4 | 2.0 | 3.4 | ∗ | 5.0 | 8.5 | 9.8 | ∗ | 4.9 | 6.1 | 9.0 | ∗ |
Congestive heart failure (%) | 3.0 | 3.1 | 5.6 | ∗ | 3.7 | 3.6 | 4.3 | 7.4 | 10.1 | 11.4 | ∗ | 8.5 | 8.8 | 10.2 | ∗ | |
Arrythmia (%) | 3.1 | 3.4 | 3.7 | 3.3 | 3.5 | 3.3 | 7.6 | 7.5 | 8.4 | 8.6 | 7.7 | 7.8 | ||||
Cerebrovascular disease (%) | 1.0 | 1.4 | 2.3 | ∗ | 1.5 | 1.3 | 1.8 | 3.1 | 3.4 | 4.5 | ∗ | 1.9 | 3.3 | 4.1 | ∗ | |
Pulmonary oedema | 0.1 | 0.2 | 0.5 | ∗ | 0.1 | 0.2 | 0.4 | ∗ | 0.7 | 0.6 | 1.0 | 0.7 | 0.9 | 0.7 | ||
Diabetes (%) | 5.2 | 6.9 | 10.3 | ∗ | 5.5 | 6.5 | 8.9 | ∗ | 7.3 | 8.5 | 10.9 | ∗ | 6.2 | 8.0 | 9.7 | ∗ |
Renal failure (%) | 0.4 | 0.7 | 1.2 | ∗ | 0.5 | 0.6 | 1.0 | ∗ | 1.0 | 1.1 | 1.2 | 1.3 | 1.3 | 1.0 | ||
Liver disease (%) | 0.1 | 0.1 | 0.3 | ∗ | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.3 | 0.2 | 0.3 | 0.1 | |||
Malignancy (%) | 0.5 | 0.8 | 1.1 | ∗ | 0.8 | 0.8 | 0.8 | 2.3 | 2.4 | 2.1 | 2.5 | 2.4 | 2.2 | |||
Cardiogenic shock (%) | 0.2 | 0.2 | 0.4 | 0.1 | 0.3 | 0.3 | 0.5 | 0.5 | 0.7 | 0.3 | 0.5 | 0.6 | ||||
Admitting hospital type | ||||||||||||||||
Cardiac care centre (%) | 16.2 | 15.0 | 15.1 | 19.5 | 15.2 | 14.5 | ∗ | 16.5 | 14.1 | 13.8 | ∗ | 18.4 | 16.4 | 13.5 | ∗ | |
Main regional hospital (%) | 64.3 | 61.6 | 60.9 | ∗ | 62.1 | 63.6 | 61.1 | ∗ | 62.5 | 60.4 | 58.0 | ∗ | 60.3 | 64.2 | 58.4 | ∗ |
Local hospital (%) | 19.5 | 23.4 | 23.9 | ∗ | 18.5 | 21.2 | 24.5 | ∗ | 21.1 | 25.5 | 28.2 | ∗ | 21.3 | 19.3 | 28.1 | ∗ |
Revascularisation§ | 38.0 | 33.2 | 28.1 | ∗ | 37.6 | 35.0 | 30.0 | ∗ | 28.1 | 25.2 | 18.6 | ∗ | 30.6 | 27.8 | 21.2 | ∗ |
COPD, chronic obstructive pulmonary disease
∗p<0.05 in univariate test for trend between income levels or educational levels.
†Claim of prescription within 6 months before index admission.
‡International Classification of Diseases (ICD) version 10 codes: COPD + asthma, J40.x-J46.x; congestive heart failure, I50.x; arrythmia, I46.x-I49.x; cerebrovascular disease, I60.x-I69.x; pulmonary oedema, J18.2, J81.x; diabetes, E10.x-E14.x; renal failure, N17.x-N19.x, I12.x, I13.x, R34.x, T85.8, T85.9, Z99.2; liver disease, K70.x-K77.x; malignancy, C00.x-C97.x; cardiogenic shock, R57.x.
§Coronary-artery bypass surgery or percutaneous coronary intervention within 6 months of admission (Danish version of the Nordic Classification of Surgical Procedures: KFN.x).